Humoral immunogenicity of an HIV-1 envelope residue 649-684 membrane-proximal region peptide fused to the plague antigen F1-V

Vaccine

Volumn 29, Issue 34, 2011, Pages 5584-5590

  Matoba, Nobuyuki ^a   Shah, Namrata Rahul ^a   Mor, Tsafrir S ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Fusion protein; Gp41 membrane proximal external region; HIV AIDS; Plague F1 V antigen; Prime boost immunization; Subunit vaccine

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; HYBRID PROTEIN; PEPTIDE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCYTOSIS; VIRUS ENVELOPE;

ANIMALS; BACTERIAL PROTEINS; CHOLERA TOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VACCINATION; VIRAL VACCINES;

EID: 79960563686     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.007     Document Type: Article

References (27)

1. Global report: UNAIDS report on the global AIDS epidemic | 2010. Joint United Nations Programme on HIV/AIDS; 2010.
2. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464(March (7286)):217-223.
3. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10(January (1)):11-23.
4. Ahlers J.D., Belyakov I.M. Strategies for optimizing targeting and delivery of mucosal HIV vaccines. Eur J Immunol 2009, 39(October (10)):2657-2669.
5. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997, 3(January (1)):42-47.
6. Alfsen A., Iniguez P., Bouguyon E., Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001, 166(May (10)):6257-6265.
7. Yu H., Alfsen A., Tudor D., Bomsel M. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent. Cell calcium 2008, 43(January (1)):73-82.
8. Alfsen A., Yu H., Magerus-Chatinet A., Schmitt A., Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005, 16(September (9)):4267-4279.
9. Alfsen A., Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002, 277(July (28)):25649-25659.
10. Matoba N., Kajiura H., Cherni I., Doran J.D., Bomsel M., Fujiyama K., et al. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR(649-684). Plant Biotechnol J 2009, 7(February (2)):129-145.
11. Matoba N., Griffin T.A., Mittman M., Doran J.D., Hanson C.V., Montefiori D., et al. Transcytosis-blocking Abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res 2008, 6(3):218-229.
12. Matoba N., Geyer B.C., Kilbourne J., Alfsen A., Bomsel M., Mor T.S. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24(June (23)):5047-5055.
13. Matoba N., Magerus A., Geyer B.C., Zhang Y., Muralidharan M., Alfsen A., et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 2004, 101(September (37)):13584-13589.
14. Feodorova V.A., Corbel M.J. Prospects for new plague vaccines. Expert Rev Vaccines 2009, 8(December (12)):1721-1738.
15. Williamson E.D. Plague. Vaccine 2009, 27(November (Suppl 4)):D56-60.
16. Kingston R., Burke F., Robinson J.H., Bedford P.A., Jones S.M., Knight S.C., et al. The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses. Clin Exp Immunol 2007, 149(September (3)):561-569.
17. Del Prete G., Santi L., Andrianaivoarimanana V., Amedei A., Domarle O., D'Elios M.M., et al. Plant-derived recombinant F1, V, and F1-V fusion antigens of Yersinia pestis activate human cells of the innate and adaptive immune system. Int J Immunopathol Pharmacol 2009, 22(January-March (1)):133-143.
18. Santi L., Giritch A., Roy C.J., Marillonnet S., Klimyuk V., Gleba Y., et al. Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA 2006, 103(January (4)):861-866.
19. Gill S.C., von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989, 182(November (2)):319-326.
20. Hocini H., Barra A., Belec L., Iscaki S., Preud'homme J.L., Pillot J., et al. Systemic and secretory humoral immunity in the normal human vaginal tract. Scand J Immunol 1995, 42(August (2)):269-274.
21. Yoshida M., Claypool S.M., Wagner J.S., Mizoguchi E., Mizoguchi A., Roopenian D.C., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004, 20(June (6)):769-783.
22. Yoshida M., Masuda A., Kuo T.T., Kobayashi K., Claypool S.M., Takagawa T., et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol 2006, 28(December (4)):397-403.
23. Wright A., Lamm M.E., Huang Y.T. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol 2008, 82(December (23)):11526-11535.
24. Jain S., Patrick A.J., Rosenthal K.L. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen. Vaccine 2010, 28(October (43)):7070-7080.
25. Denton P.W., Garcia J.V. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep 2009, 6(February (1)):13-19.
26. Genesca M., Miller C.J. Use of nonhuman primate models to develop mucosal AIDS vaccines. Curr HIV/AIDS Rep 2010, 7(February (1)):19-27.
27. Merbah M., Introini A., Fitzgerald W., Grivel J.C., Lisco A., Vanpouille C., et al. Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol 2011, 65(March (3)):268-278.